- Moderna Reports Positive Early Data for COVID-19 Vaccine Candidate (drugtopics.com)Moderna taps $1.34B stock offering to bankroll its promising COVID-19 vaccine (fiercepharma.com)
Moderna announced new interim clinical data results for its coronavirus disease 2019 (COVID-19) vaccine candidate from a phase 1 study...The investigational vaccine, called mRNA-1273, was launched...on March 16, making it the first trial to be started in humans for a vaccine for this virus...Tal Zaks, MD, PhD, chief medical officer at Moderna, said in a statement. “When combined with the success in preventing viral replication in the lungs of a pre-clinical challenge model at a dose that elicited similar levels of neutralizing antibodies, these data substantiate our belief that mRNA-1273 has the potential to prevent COVID-19 disease and advance our ability to select a dose for pivotal trials.”...Moderna expects to begin its phase 3 study in July 2020...READ MORE
- FDA giving White House new guidance on rapid COVID-19 test (apnews.com)
The head of the Food and Drug Administration said Friday his agency has provided new guidance to the White House after data suggested that a rapid COVID-19 test used by President Donald Trump and others every day may provide inaccuracies and false negatives...Commissioner Steve Hahn said that if a person is suspected of having the disease caused by the coronavirus, “it might be worth, if the test is negative, getting a second confirmatory test. That’s what our guidance is about.”...The test, by Abbott Laboratories, is used daily at the White House to test Trump and key members of his staff, including the coronavirus task force. The FDA said late Thursday it was investigating preliminary data suggesting the 15-minute test can miss COVID-19 cases, falsely clearing infected patients...READ MORE
- How Coronavirus Shutdowns Are Killing America’s Health Care System (thefederalist.com)
Doctors on the front lines of the COVID-19 fight really are heroes, but don’t forget about the tens of thousands of 'backline doctors' who are equally at risk, physically and financially...President Trump has compared the fight against COVID-19 to a war against a silent enemy. The soldiers on the front lines are the doctors, nurses, technicians, and others who are fighting it in hospitals across the United States...The untold story, however, is of the hundreds of thousands of doctors facing not only the health risks of caring for patients with undiagnosed COVID-19, but also ruinous financial calamity and professional catastrophe, self-inflicted by government...Now our health-care system is poised to implode...Many patients need care, and not just those with COVID-19. To ensure our system can recover, federal and state governments should implement a few basic provisions.
- ...the federal government should indemnify doctors against frivolous lawsuits that result from this pandemic.
- ...the federal government should make available interest-free loans to doctors who feel they cannot reopen offices because of financial hardship inflicted by COVID-19-related mandates. This is important to prevent wholesale migration of small practices to hospitals.
- ...the federal government should seize this once-in-a-century opportunity to decimate the bureaucracy impeding innovation in medicine. Cutting red tape will stimulate a wave of doctor-led creativity, which is now constrained by onerous laws, such as Stark laws, which restrict collaboration.
- ...the reprieves that have allowed telemedicine to expand during this pandemic should be made permanent. Doctors need to continue to be paid for these services just as they would for office visits, and be allowed to deliver these services across state lines.
- ...the playing field in health care needs to be leveled, giving more control to doctors and less to hospitals. State lawmakers should repeal certificate-of-need laws, which prevent competition and the opening of new facilities in certain areas. We were underprepared for this pandemic in part because of hospital consolidation. More resources, not fewer, would provide helpful redundancy and protection against the next pandemic...READ MORE
- Quest Diagnostics launches first consumer-ordered COVID-19 antibody test (fiercehealthcare.com)
For about $120, anyone can get now get a COVID-19 antibody test from Quest Diagnostics...The lab company announced Tuesday it launched the first consumer-ordered test—yes, that means there's no doctor referral needed—to allow patients to check whether they have the antibodies that indicate they've had the novel coronavirus and may have some immunity to it...The test will be available through QuestDirect, which is Quest's consumer-initiated testing business. Antibody testing uses blood serum specimens and is sometimes referred to as serology testing...READ MORE
- NACDS COVID-19 Report: Top Reopening Priorities and How Pharmacies Can Help (drugtopics.com)Pharmacies: A Vital Partner in Reopening America (nacds.org)
Rapid coronavirus disease 2 (COVID-19) testing, contract tracing, and preparing for vaccines and treatments are the 3 key priorities as the United States reopens, NACDS said in a new report...Pharmacies: A Vital Partner in Reopening America...The organization also urged that additional steps should be taken to ensure that pharmacists and pharmacies are fully utilized to support this national effort...READ MORE
- FDA Continues Fight Against Fraudulent COVID-19 Treatments (pharmtech.com)
In its effort to combat fraudulent medical products that claim to prevent or treat COVID-19, FDA has issued 42 warning letters, as of May 7, 2020, to companies promoting unproven products claiming to prevent, treat, diagnose, or even cure COVID-19...The agency’s Operation Quack Hack has discovered hundreds of fraudulent drugs, testing kits, and personal protective equipment sold online. FDA has sent numerous abuse complaints to domain name registrars and Internet marketplaces, who the agency says have voluntarily removed the identified postings. “We will continue to monitor the online ecosystem for fraudulent products peddled by bad actors seeking to profit from this global pandemic. We encourage anyone aware of suspected fraudulent medical products for COVID-19 to report them to the FDA,” the agency said in a press release...READ MORE
- With the world waiting, Roche socks $459M into COVID-19 antibody test production (fiercepharma.com)
Roche scored a major win with the FDA's backing for its COVID-19 antibody tests last week in a field marked by products of questionable quality...Roche will plow $459 million into its manufacturing facility in Penzberg, Germany, to boost production of the antibody test that won an emergency use authorization from the FDA last week...Roche CEO Severin Schwan blasted the current state of COVID-19 serology tests, calling many of the diagnostics "amateur."...“These tests are not worth anything, or have very little use,”...READ MORE
- With drugmakers clamoring, FDA looks to restart facility inspections delayed by COVID-19 (fiercepharma.com)
The FDA abruptly shut down its on-site facility inspections in March, hoping to keep its employees safe during the novel coronavirus pandemic. More than two months into that moratorium, drugmakers are calling for relief—and with some new guidance, the FDA shows it might be willing to accommodate...The agency is working with the U.S. Centers for Disease Control and Prevention to develop a "phased approach" to restarting inspections of domestic and foreign drug manufacturing facilities, the administration said...the plan would likely continue the agency's focus on high-priority inspections taken on a "case-by-case" basis...READ MORE
- Indian pharmas call on FDA to perform ‘virtual’ facility checks during COVID-19 inspection lockdown (fiercepharma.com)
India, one of the largest drug exporters in the world, has been hit hard by the novel coronavirus pandemic as global lockdowns have complicated daily operations. On one measure—the FDA's nearly two-month ban on foreign inspections—Indian drugmakers are pushing back. And they may have come up with a novel solution...Major Indian pharmaceutical companies are asking the FDA to conduct "desk reviews" or virtual facility inspections during the pandemic in order to "ensure the continuous supply of much-needed drugs in the United States," according to a letter from the Indian Pharmaceutical Alliance...The group also requested the FDA consider recognizing inspections by foreign regulators and temporarily waiving on-site inspections "based on past inspection history and the critical nature of products, such as drug shortages or products that do not currently have generic alternatives."...READ MORE
- U.S. targets fraud in coronavirus antibody test market with tighter rules (reuters.com)
The United States on Monday began requiring antibody tests for the new coronavirus to undergo a regulatory agency review, acknowledging that its earlier policy had opened the door to fraud...The U.S. Food and Drug Administration had previously required only that companies attest their product was valid and labeled as unapproved, attracting 170 companies to the antibody test market including unscrupulous vendors making false claims...When the FDA put the policy in place on March 16th, it had been under pressure to move fast following a slow ramp up of COVID-19 diagnostic tests that hindered public health efforts...“Flexibility never meant we would allow fraud. We unfortunately see unscrupulous actors marketing fraudulent test kits and using the pandemic as an opportunity to take advantage of Americans’ anxiety,” the FDA said in a statement...READ MORE